placebo + dapagliflozin

The combination of placebo + dapagliflozin refers to the control arm used in Phase III clinical trials sponsored by AstraZeneca, specifically those evaluating the efficacy of the aldosterone synthase inhibitor baxdrostat. This combination consists of the approved SGLT2 inhibitor dapagliflozin and a matching placebo. Dapagliflozin is a small molecule that selectively inhibits the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, which reduces glucose reabsorption and promotes osmotic diuresis. This mechanism leads to improved glycemic control, blood pressure reduction, and significant renal and cardiovascular protection. In the context of chronic kidney disease (CKD) and hypertension, this combination serves as the standard-of-care comparator to assess whether adding baxdrostat to dapagliflozin provides superior outcomes in reducing renal disease progression and cardiovascular mortality.

Other names

Dapagliflozin alonePlacebo/dapagliflozin